Octreotide for malignant bowel obstruction: Twenty years after

Malignant bowel obstruction (MBO) is a challenging complication of advanced cancer. Conservative treatment of inoperable MBO in terminal cancer patients has been found to be effective in controlling the distressing symptoms caused by this complication in inoperable cancer patients. Twenty years ago, octreotide was proposed to treat symptoms related to malignant bowel obstruction. Since then several reports have confirmed the efficacy of octreotide in the management of gastrointestinal symptoms of MBO. Fifteen randomized controlled trials or observational reports with a significant number of patients treated with octreotide have been reviewed; 281 patients were surveyed. Authors reported a therapeutic success ranging between 60% and 90%. Despite the limited number of controlled studies, the large experience acquired through 20 years suggests that octreotide is the first-choice antisecretory agent for MBO. As such, octreotide is the only drug approved by the health-care system in Italy for this treatment.

► We presented the original idea regarding the rationale of using octrotide in maligant bowel obstruction.
► We presented the subsequent literature supporting the efficacy of octreotide.
► Despite existing studies used different evaluation tools, in general the success rate of octrotide in managing symptoms associated with malignant bowel obstruction is high.
► No other drug has shown the same efficacy.